|
WO2021041555A1
|
|
Methods and compositions for culturing alveolar cells
|
|
US2021054009A1
|
|
Treprostinil prodrugs
|
|
US2021052641A1
|
|
Pre-conditioned extracellular vesicles and methods of production
|
|
US2021008106A1
|
|
Mitochondrial treatment of organs for transplantation
|
|
WO2020243016A1
|
|
Systems and methods for exchanging small molecules with fluid
|
|
WO2020086367A1
|
|
Synthesis of esuberaprost prodrugs
|
|
CA3098891A1
|
|
Apparatus and method for controlling fluid flow
|
|
US2018296606A1
|
|
Extracellular vesicles with enhanced potency
|
|
US2018325908A1
|
|
Methods and compositions for treating pulmonary hypertension
|
|
CN110177559A
|
|
Treprostinil enhanced MSC immunological regulation performance
|
|
EP3515430A1
|
|
Treprostinil prodrugs
|
|
CN110022887A
|
|
Extracellular vesica with enhancing effect
|
|
US2018193869A1
|
|
Aerosol delivery device and method for manufacturing and operating the same
|
|
EP3565621A1
|
|
Aerosol delivery device and method for manufacturing and operating the same
|
|
KR20180061159A
|
|
How to make Vera Frost
|
|
KR20170113531A
|
|
Synthesis of intermediate for producing prostacyclin derivatives
|
|
WO2016036764A2
|
|
Automated bioreactor system, system for automatically implementing protocol for decellularizing organ, and waste decontamination system
|
|
KR20170016955A
|
|
Treprostinil formulations
|
|
US2014288179A1
|
|
Stable solutions of treprostinil
|
|
EP2991639A1
|
|
Controlled release pharmaceutical formulations
|
